It is consistent with the results of previous studies on TSPO ligands, such as YL-IPA08 and AC-5216, which have been shown to display efficacy toward the treatment of psychiatric disorders by increasing neurosteroid biosynthesis in the brain, inducing anxiolytic and antidepressant activities in some rodent models and improving behavioral deficits in a mouse model of PTSD (Qiu et al., 2013; Zhang et al., 2014a; Wang et al., 2016; Li et al., 2017; Zhang L.M. et al., 2017). The gene discussed is TSPO; the disease is post-traumatic stress disorder.